IN
Inhibitor Therapeutics, Inc.
INTI · OTC
$0.06 -32.92% (-$0.03)
1M -32.92%
Market Cap $10.3M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.04
33.0% downside
Current Price
$0.06
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INTI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A P/B N/A
EV/FFO N/A
P/E N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor ROA 519.14%
Asset turnover 0.00x
ROIC 689.90%
Debt
100 /100
Low Current ratio 3.36x
Debt/Assets N/A
Net debt/EBITDA N/A
Stability
19 /100
Unstable EPS volatility 89.29%
Profitable years 0
Beta -0.70x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INTI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Francis E. O'Donnell Jr.
Employees
8
Headquarters
Tampa